Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GENELUX CorpGNLX · Entity 1116 | General Counsel | June 16, 2026 | June 18, 2026 |
| Rani Therapeutics Holdings, Inc.RANI · Entity 6642 | General Counsel | March 21, 2024 | March 23, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GENELUX Corp
Report date June 16, 2026 · Filed June 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 233,957 |
Reported balance
After 2026-06-16 transaction · row 1
1 source rowRow 1 · 2026-06-16 · Grant · Acquired 233,957 · Balance 233,957 F1: Represents restricted stock units ("RSUs") granted pursuant to the Issuer's 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of common stock upon vesting. The RSUs will vest 25% on the first anniversary of the date of grant, and the remaining shares shall vest in 12 equal quarterly (every 3 months) installments thereafter |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units ("RSUs") granted pursuant to the Issuer's 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of common stock upon vesting. The RSUs will vest 25% on the first anniversary of the date of grant, and the remaining shares shall vest in 12 equal quarterly (every 3 months) installments thereafter
Rani Therapeutics Holdings, Inc.
Report date March 21, 2024 · Filed March 23, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.60 · Expires 2034-03-20 | Direct | 323,500 |
Reported balance
After 2024-03-21 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-03-21 · Grant · Acquired 323,500 · Balance 323,500 F1: The shares subject to the option vest as follows: 1/48th of the shares subject to the option vest monthly over four years from March 21, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option vest as follows: 1/48th of the shares subject to the option vest monthly over four years from March 21, 2024.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 16, 2026 Filed Jun 18, 2026 23:05 UTC | GENELUX Corp GNLX · Entity 1116 | GrantCommon Stock | 233,957 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-26-029420 · ownership.xml · nonDerivative · entry 1 Groen Eric · CIK 0001918630 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 233,957 F1 · kind: Represents restricted stock units ("RSUs") granted pursuant to the Issuer's 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of common stock upon vesting. The RSUs will vest 25% on the first anniversary of the date of grant, and the remaining shares shall vest in 12 equal quarterly (every 3 months) installments thereafter Read SEC document |
| July 01, 2025 Filed Jul 2, 2025 20:16 UTC | GENELUX Corp GNLX · Entity 1116 | GrantStock Option (Right to Buy) · Derivative | 270,000 | $0.00 Strike: $2.83 | $0.00 |
DisclosureSEC source: 0001415889-25-019032 · form4-07022025_080748.xml · derivative · entry 1 Groen Eric · CIK 0001918630 · General Counsel & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 270,000 Underlying: Common Stock · 270,000 shares Expires 2035-06-30 F1 · derivative.exercise_date: 25% of the shares shall vest on July 1, 2026, and the remaining shares shall vest in 36 equal monthly installments thereafter. Read SEC document |
| March 21, 2024 Filed Mar 23, 2024 01:00 UTC | Rani Therapeutics Holdings, Inc. RANI · Entity 6642 | GrantStock Option (Right to Buy) · Derivative | 323,500 | $0.00 Strike: $3.60 | $0.00 |
DisclosureSEC source: 0000950170-24-035572 · ownership.xml · derivative · entry 1 Groen Eric · CIK 0001918630 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 323,500 Underlying: Class A Common Stock · 323,500 shares Expires 2034-03-20 F1 · derivative.exercise_date: The shares subject to the option vest as follows: 1/48th of the shares subject to the option vest monthly over four years from March 21, 2024. Read SEC document |
| December 16, 2023 Filed Dec 19, 2023 21:05 UTC | Rani Therapeutics Holdings, Inc. RANI · Entity 6642 | GrantStock Option (Right to Buy) · Derivative | 54,167 | Not disclosed Strike: $2.84 | Not disclosed |
DisclosureSEC source: 0000950170-23-071476 · ownership.xml · derivative · entry 6 Groen Eric · CIK 0001918630 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,167 Underlying: Class A Common Stock · 54,167 shares Expires 2031-07-28 F3 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on December 16, 2023 (the "Repricing Date"). Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.84 per share, the closing price of the Issuer's Common Stock on the Repricing Date. There is no change to the expiration dates or the vesting schedule of the repriced options. F5 · derivative.exercise_date: The shares subject to the option vest as follows: 25% of the shares subject to the option vest on July 29, 2022; and 1/48th of the shares subject to the option vest monthly over the remaining three years. Read SEC document |
| December 16, 2023 Filed Dec 19, 2023 21:05 UTC | Rani Therapeutics Holdings, Inc. RANI · Entity 6642 | Disposition to issuerStock Option (Right to Buy) · Derivative | 54,167 | Not disclosed Strike: $11.00 | Not disclosed |
DisclosureSEC source: 0000950170-23-071476 · ownership.xml · derivative · entry 5 Groen Eric · CIK 0001918630 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,833 Underlying: Class A Common Stock · 54,167 shares Expires 2031-07-28 F3 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on December 16, 2023 (the "Repricing Date"). Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.84 per share, the closing price of the Issuer's Common Stock on the Repricing Date. There is no change to the expiration dates or the vesting schedule of the repriced options. F2 · derivative.exercise_date: The remaining shares subject to the option are fully vested and exercisable as of the Repricing Date. F5 · derivative.exercise_date: The shares subject to the option vest as follows: 25% of the shares subject to the option vest on July 29, 2022; and 1/48th of the shares subject to the option vest monthly over the remaining three years. Read SEC document |
| December 16, 2023 Filed Dec 19, 2023 21:05 UTC | Rani Therapeutics Holdings, Inc. RANI · Entity 6642 | GrantStock Option (Right to Buy) · Derivative | 43,400 | Not disclosed Strike: $2.84 | Not disclosed |
DisclosureSEC source: 0000950170-23-071476 · ownership.xml · derivative · entry 4 Groen Eric · CIK 0001918630 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,400 Underlying: Class A Common Stock · 43,400 shares Expires 2032-03-21 F3 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on December 16, 2023 (the "Repricing Date"). Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.84 per share, the closing price of the Issuer's Common Stock on the Repricing Date. There is no change to the expiration dates or the vesting schedule of the repriced options. F4 · derivative.exercise_date: The shares subject to the option vest as follows: 1/48th of the shares subject to the option vest monthly over four years from March 22, 2022. Read SEC document |
| December 16, 2023 Filed Dec 19, 2023 21:05 UTC | Rani Therapeutics Holdings, Inc. RANI · Entity 6642 | Disposition to issuerStock Option (Right to Buy) · Derivative | 43,400 | Not disclosed Strike: $13.21 | Not disclosed |
DisclosureSEC source: 0000950170-23-071476 · ownership.xml · derivative · entry 3 Groen Eric · CIK 0001918630 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,000 Underlying: Class A Common Stock · 43,400 shares Expires 2032-03-21 F3 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on December 16, 2023 (the "Repricing Date"). Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.84 per share, the closing price of the Issuer's Common Stock on the Repricing Date. There is no change to the expiration dates or the vesting schedule of the repriced options. F2 · derivative.exercise_date: The remaining shares subject to the option are fully vested and exercisable as of the Repricing Date. F4 · derivative.exercise_date: The shares subject to the option vest as follows: 1/48th of the shares subject to the option vest monthly over four years from March 22, 2022. F2 · balance_after: The remaining shares subject to the option are fully vested and exercisable as of the Repricing Date. Read SEC document |
| December 16, 2023 Filed Dec 19, 2023 21:05 UTC | Rani Therapeutics Holdings, Inc. RANI · Entity 6642 | GrantStock Option (Right to Buy) · Derivative | 171,500 | Not disclosed Strike: $2.84 | Not disclosed |
DisclosureSEC source: 0000950170-23-071476 · ownership.xml · derivative · entry 2 Groen Eric · CIK 0001918630 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 171,500 Underlying: Class A Common Stock · 171,500 shares Expires 2033-03-26 F3 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on December 16, 2023 (the "Repricing Date"). Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.84 per share, the closing price of the Issuer's Common Stock on the Repricing Date. There is no change to the expiration dates or the vesting schedule of the repriced options. F1 · derivative.exercise_date: The shares subject to the option vest as follows: 1/48th of the shares subject to the option vest monthly over four years from March 27, 2023. Read SEC document |
| December 16, 2023 Filed Dec 19, 2023 21:05 UTC | Rani Therapeutics Holdings, Inc. RANI · Entity 6642 | Disposition to issuerStock Option (Right to Buy) · Derivative | 171,500 | Not disclosed Strike: $5.44 | Not disclosed |
DisclosureSEC source: 0000950170-23-071476 · ownership.xml · derivative · entry 1 Groen Eric · CIK 0001918630 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,300 Underlying: Class A Common Stock · 171,500 shares Expires 2033-03-26 F3 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on December 16, 2023 (the "Repricing Date"). Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.84 per share, the closing price of the Issuer's Common Stock on the Repricing Date. There is no change to the expiration dates or the vesting schedule of the repriced options. F1 · derivative.exercise_date: The shares subject to the option vest as follows: 1/48th of the shares subject to the option vest monthly over four years from March 27, 2023. F2 · derivative.exercise_date: The remaining shares subject to the option are fully vested and exercisable as of the Repricing Date. F2 · balance_after: The remaining shares subject to the option are fully vested and exercisable as of the Repricing Date. Read SEC document |
| March 27, 2023 Filed Mar 30, 2023 01:12 UTC | Rani Therapeutics Holdings, Inc. RANI · Entity 6642 | GrantStock Option (Right to Buy) · Derivative | 205,800 | $0.00 Strike: $5.44 | $0.00 |
DisclosureSEC source: 0001415889-23-005600 · form4-03302023_010335.xml · derivative · entry 2 Groen Eric · CIK 0001918630 · GENERAL COUNSEL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 205,800 Underlying: Class A Common Stock · 205,800 shares Expires 2033-03-26 F2 · derivative.exercise_date: The shares subject to the option vest as follows: 1/4th of the shares subject to the option vest monthly over four years from March 27, 2023. Read SEC document |
| March 27, 2023 Filed Mar 30, 2023 01:12 UTC | Rani Therapeutics Holdings, Inc. RANI · Entity 6642 | GrantClass A Common Stock | 139,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-005600 · form4-03302023_010335.xml · nonDerivative · entry 1 Groen Eric · CIK 0001918630 · GENERAL COUNSEL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 163,216 F1 · date: The shares subject to the restricted stock unit grant vest as follows: 1/16th of the RSUs shall vest quarterly over four years from March 27, 2023. Read SEC document |
| March 22, 2023 Filed Mar 24, 2023 20:05 UTC | Rani Therapeutics Holdings, Inc. RANI · Entity 6642 | Tax withholdingClass A Common Stock | 2,498 | $5.95 | $14,863.10 |
DisclosureSEC source: 0000899243-23-009586 · doc4.xml · nonDerivative · entry 1 Groen Eric · CIK 0001918630 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,216 F1 · shares: Represents the number of shares withheld by and surrendered to the Issuer on March 22, 2023, to satisfy tax withholding obligations that arose in connection with the vesting of the restricted stock units granted to Mr. Groen on March 22, 2022. F2 · balance_after: Includes 2,214 shares acquired under the Issuer's 2021 Employee Stock Purchase Plan on December 1, 2022. Read SEC document |
| March 22, 2022 Filed Mar 25, 2022 01:01 UTC | Rani Therapeutics Holdings, Inc. RANI · Entity 6642 | GrantStock Option (Right to Buy) · Derivative | 74,400 | $0.00 Strike: $13.21 | $0.00 |
DisclosureSEC source: 0001209191-22-021014 · doc4.xml · derivative · entry 2 Groen Eric · CIK 0001918630 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,400 Underlying: Class A Common Stock · 74,400 shares Expires 2032-03-21 F2 · derivative.exercise_date: The shares subject to the option vest as follows: 1/48th of the shares subject to the option vest monthly over four years from March 22, 2022. Read SEC document |
| March 22, 2022 Filed Mar 25, 2022 01:01 UTC | Rani Therapeutics Holdings, Inc. RANI · Entity 6642 | GrantClass A Common Stock | 24,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-021014 · doc4.xml · nonDerivative · entry 1 Groen Eric · CIK 0001918630 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,500 F1 · deemedExecutionDate: The shares subject to the restricted stock unit grant vest as follows: 25% of the RSUs shall vest yearly over four years from March 22, 2022. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.